For Healthcare Professionals Outside the US
KISQALI is indicated for the treatment of women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)—negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre‑ or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone‑releasing hormone (LHRH) agonist.


Click here for important information regarding nitrosamine levels related to investigational use of ribociclib in early breast cancer

It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

As demonstrated in MONALEESA-21


First-line OS data in postmenopausal patients with an AI



Additional OS data in premenopausal patients with ET



OS data in postmenopausal patients with fulvestrant


aBC, advanced breast cancer; AI, aromatase inhibitor; CDK, cyclin-dependent kinase; ET, endocrine therapy; OS, overall survival.
Reference: 1. Data on file. Novartis Pharma AG; 2021.